The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Yervoy

5 milligram(s)/millilitre Concentrate for solution for infusion

Bristol-Myers Squibb Pharma EEIGEU/1/11/698/001-002

Main Information

Trade NameYervoy
Active SubstancesIpilimumab
Strength5 milligram(s)/millilitre
Dosage FormConcentrate for solution for infusion
Licence HolderBristol-Myers Squibb Pharma EEIG
Licence NumberEU/1/11/698/001-002

Group Information

ATC CodeL01XC Monoclonal antibodies
L01XC11 ipilimumab

Status

Authorised/WithdrawnAuthorised
Licence Issued
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2).
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website

Educational Materials - HCP

Educational Materials - Patient

« Back